Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 49Carcinoma, Renal Cell 30Neoplasm Metastasis 18Neoplasms 15Kidney Neoplasms 14Neuroendocrine Tumors 11Carcinoma, Neuroendocrine 9Prostatic Neoplasms 7Melanoma 7Triple Negative Breast Neoplasms 6Thyroid Neoplasms 6Sarcoma 6Meningioma 6Lymphoma 6Glioma 6Endometrial Neoplasms 6Tuberous Sclerosis 5Stomach Neoplasms 5Recurrence 5Lymphoma, Mantle-Cell 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoma 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Liver Neoplasms 4Carcinoma, Islet Cell 4Astrocytoma 4

Interventions

lutetium Lu 177 dotatate 4Temozolomide 4anlotinib 3Specimen Handling 3cabozantinib 2belzutifan 2Sunitinib 2Magnetic Resonance Spectroscopy 2Axitinib 23-Iodobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2talazoparib 1pembrolizumab 1pazopanib 1olaparib 1lanreotide 1guadecitabine 1gallium Ga 68 dotatate 1copper dotatate CU-64 1atezolizumab 1ONC206 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Paraganglioma × Everolimus × Clear all
NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

University of California, San Francisco

Phase 2 Terminated
17 enrolled 10 charts
CNSEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡